晨光生物
(300138)
| 流通市值：54.05亿 | | | 总市值：65.56亿 |
| 流通股本：3.98亿 | | | 总股本：4.83亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 5,047,254,465.57 | 3,657,547,726.71 | 1,716,472,687.32 | 6,994,192,786.23 |
| 营业收入 | 5,047,254,465.57 | 3,657,547,726.71 | 1,716,472,687.32 | 6,994,192,786.23 |
| 二、营业总成本 | 4,718,060,635.45 | 3,432,495,143.03 | 1,605,425,014.2 | 6,868,044,529.72 |
| 营业成本 | 4,316,379,997.65 | 3,150,505,383.71 | 1,473,470,723.79 | 6,437,297,116.3 |
| 税金及附加 | 19,490,379.39 | 13,248,310.75 | 7,020,357.25 | 19,180,239.35 |
| 销售费用 | 45,953,832.36 | 27,213,459.91 | 12,345,145.41 | 50,140,684.42 |
| 管理费用 | 136,247,370.54 | 88,595,651.8 | 43,655,262.73 | 160,557,194.85 |
| 研发费用 | 159,491,892.98 | 112,379,706.36 | 41,738,594.25 | 128,602,770.25 |
| 财务费用 | 40,497,162.53 | 40,552,630.5 | 27,194,930.77 | 72,266,524.55 |
| 其中:利息费用 | 70,036,521.24 | 58,758,941.51 | 33,854,519.77 | 114,417,669.76 |
| 其中:利息收入 | 31,933,849.65 | 21,426,871.28 | 9,565,581.63 | 40,574,981.05 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 4,167,742.31 | 2,296,924.13 | 1,257,597.41 | -5,111,280.46 |
| 加:投资收益 | 31,939,889.39 | 27,436,415.66 | 12,924,632.22 | 17,787,444.36 |
| 资产处置收益 | 3,782,019.01 | 3,982,574.33 | 4,034,011.68 | 4,887,839.58 |
| 资产减值损失(新) | -24,896,091.54 | -13,183,693.56 | -7,922,514.3 | -95,164,207.13 |
| 信用减值损失(新) | 1,086,476.53 | 1,582,556.48 | 3,078,566.4 | -3,809,661.36 |
| 其他收益 | 23,421,591.34 | 16,801,006.73 | 5,393,676.59 | 61,297,185.21 |
| 四、营业利润 | 368,695,457.16 | 263,968,367.45 | 129,813,643.12 | 106,035,576.71 |
| 加:营业外收入 | 5,532,865.87 | 2,818,784.39 | 1,626,364.56 | 38,821,823.51 |
| 减:营业外支出 | 3,881,742.54 | 1,925,993.63 | 156,682.09 | 37,912,075.51 |
| 五、利润总额 | 370,346,580.49 | 264,861,158.21 | 131,283,325.59 | 106,945,324.71 |
| 减:所得税费用 | 59,017,512.04 | 43,607,413.09 | 20,095,937.65 | 28,988,211.22 |
| 六、净利润 | 311,329,068.45 | 221,253,745.12 | 111,187,387.94 | 77,957,113.49 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 311,329,068.45 | 221,253,745.12 | 111,187,387.94 | 77,957,113.49 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 303,829,082.4 | 214,971,374.27 | 109,480,325.98 | 94,049,622.14 |
| 少数股东损益 | 7,499,986.05 | 6,282,370.85 | 1,707,061.96 | -16,092,508.65 |
| 扣除非经常损益后的净利润 | 255,982,097.75 | 184,472,238.5 | 95,923,700.54 | 44,255,459.4 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.63 | 0.44 | 0.23 | 0.18 |
| (二)稀释每股收益 | 0.63 | 0.44 | 0.23 | 0.18 |
| 八、其他综合收益 | -15,928,224.68 | -2,914,508.54 | -807,209.72 | 3,336,226.69 |
| 归属于母公司股东的其他综合收益 | -15,928,224.68 | -2,914,508.54 | -807,209.72 | 3,336,226.69 |
| 九、综合收益总额 | 295,400,843.77 | 218,339,236.58 | 110,380,178.22 | 81,293,340.18 |
| 归属于母公司股东的综合收益总额 | 287,900,857.72 | 212,056,865.73 | 108,673,116.26 | 97,385,848.83 |
| 归属于少数股东的综合收益总额 | 7,499,986.05 | 6,282,370.85 | 1,707,061.96 | -16,092,508.65 |
| 公告日期 | 2025-10-25 | 2025-08-26 | 2025-04-26 | 2025-04-08 |
| 审计意见(境内) | | | | 标准无保留意见 |